Soleno became a completed deal
- Soleno’s main story changed from drug launch growth to a cash takeover by Neurocrine.
- Neurocrine agreed to pay $53.00 per share in cash for Soleno.
- The merger closed on May 18, 2026, so the old public-stock thesis is now over.
- Before the deal, VYKAT XR had produced $190.4 million of 2025 net product revenue.
- Soleno also withdrew its European filing, which weakened the old standalone growth case.
The stock story ended
Soleno is no longer a normal public equity story. On April 5, 2026, it signed a merger agreement to be bought by Neurocrine Biosciences for $53.00 per share in cash. That changed the key question from “How fast can VYKAT XR grow?” to “Will the deal close?”
That question has now been answered. Neurocrine completed the acquisition on May 18, 2026. The tender offer accepted about 46.4 million shares, or about 88.9% of Soleno’s outstanding common stock, and the remaining shares were converted into the same $53.00 per share cash price.
For a reader looking back, the bull case was simple: the tender offer closed on time and holders received cash. The bear case, deal failure or a long delay, did not happen. Any future upside or downside from VYKAT XR now belongs to Neurocrine, not standalone SLNO shareholders.
One drug, then a sale
Soleno was a rare disease biotech built around one approved product, VYKAT XR, also called diazoxide choline. The drug treats hyperphagia, or extreme hunger, in people with Prader-Willi syndrome.
The company began booking VYKAT XR sales in the second quarter of 2025. For the year ended December 31, 2025, it reported $190.4 million of net product revenue and $20.1 million of net income. That was its first profitable year.
By 2026, the business model was dominated by the Neurocrine deal. Cash from the buyer, not future prescription growth, became the main source of value for public holders.
What Neurocrine bought
VYKAT XR
VYKAT XR was Soleno’s only FDA-approved product. It treats hyperphagia in Prader-Willi syndrome and drove all disclosed product revenue in 2025.
U.S. VYKAT XR launch
The U.S. launch began in the second quarter of 2025. Revenue rose from $32.7 million in Q2 2025 to $66.0 million in Q3 2025 and $91.7 million in Q4 2025.
European VYKAT filing
Soleno withdrew its European Marketing Authorization Application in April 2026. That removed a major piece of the former standalone expansion plan.
Neurocrine integration
VYKAT XR is now part of Neurocrine after the May 2026 merger close. Future strategy, spending, and expansion decisions sit with the buyer.
No real segment mix
Soleno reported one operating focus: rare disease therapeutics led by VYKAT XR. For 2025, disclosed net product revenue was $190.4 million, and no separate revenue segment mix was provided.
What could have gone wrong
Deal failure risk
High impact · Low oddsBefore May 18, 2026, the main risk was that Neurocrine’s tender offer failed or did not meet closing conditions. That would likely have pushed the stock back toward a standalone drug-launch valuation. The deal has since closed, so this risk is now mainly historical.
Deal delay risk
Medium impact · Low oddsA delay past the expected end of Q2 2026 close would have created uncertainty and opportunity cost. Holders would have waited longer for the $53.00 per share cash payment. This did not become the final outcome.
European expansion loss
Medium impact · High oddsSoleno withdrew its European application for VYKAT XR in April 2026. That delayed any European revenue stream and removed a key part of the old standalone thesis. Neurocrine could revisit Europe later, but Soleno public holders no longer own that option.
Single-product dependence
Medium impact · Medium oddsSoleno depended on one approved drug. Before the sale, weak patient retention, payer pushback, or safety issues with VYKAT XR would have hit almost the whole business. After the acquisition, this risk moved to Neurocrine’s portfolio.
In one breath
Is Soleno Therapeutics still publicly traded?
No. Neurocrine completed the acquisition of Soleno on May 18, 2026. Soleno shares were converted into the right to receive $53.00 per share in cash.
What was Soleno’s main product?
Soleno’s main product was VYKAT XR, a diazoxide choline extended-release medicine. It was approved for hyperphagia, or extreme hunger, in Prader-Willi syndrome.
Why did the Soleno thesis change so much?
The company first looked like a rare disease launch story after VYKAT XR started selling well. The Neurocrine merger changed the stock into a merger arbitrage story, where deal closing mattered more than long-term sales growth.
What happened to Soleno’s European plan?
Soleno voluntarily withdrew its European Marketing Authorization Application in April 2026. That delayed European commercialization and weakened the old standalone growth plan.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- July 2, 2026
- Score data
- September 27, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Soleno Therapeutics, Inc. in Finn's Biotechnology industry ranking.
